# Zain Chagla

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zain-chagla/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,510 |
| Field | COVID-19 Clinical Research Studies |
| h-index | 18 |
| i10-index | 26 |
| Last Known Institution | Tampere University |
| OpenAlex ID | https://openalex.org/A5019202578 |
| ORCID iD | 0000-0002-3619-7031 |
| Works | 68 |

## Researcher papers

- [Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial](https://scholariq.org/papers/convalescent-plasma-for-hospitalized-patients-with-covid-19-an-open-label/)
- [The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach](https://scholariq.org/papers/the-risk-of-allergic-reaction-to-sars-cov-2-vaccines-and-recommended-evaluation/)
- [Novel Coronavirus COVID-19](https://scholariq.org/papers/novel-coronavirus-covid-19/)
- [The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose](https://scholariq.org/papers/the-bnt162b2-biontech-pfizer-vaccine-had-95-efficacy-against-covid-19-7-days/)
- [Medical Masks Versus N95 Respirators for Preventing COVID-19 Among Health Care Workers](https://scholariq.org/papers/medical-masks-versus-n95-respirators-for-preventing-covid-19-among-health-care/)
- [Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD](https://scholariq.org/papers/prescribing-nirmatrelvir-ritonavir-for-covid-19-in-advanced-ckd/)
- [The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials](https://scholariq.org/papers/the-efficacy-and-safety-of-hydroxychloroquine-for-covid-19-prophylaxis-a/)
- [Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19](https://scholariq.org/papers/safety-of-hydroxychloroquine-among-outpatient-clinical-trial-participants-for/)
- [Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019](https://scholariq.org/papers/early-experience-with-modified-dose-nirmatrelvir-ritonavir-in-dialysis-patients/)
- [Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects](https://scholariq.org/papers/characteristics-of-anti-sars-cov-2-antibodies-in-recovered-covid-19-subjects/)
- [Knowledge, attitudes, and practices towards Human Papilloma Virus and uptake of HPV vaccine: A protocol for a systematic review](https://scholariq.org/papers/knowledge-attitudes-and-practices-towards-human-papilloma-virus-and-uptake-of/)

## Researcher topics

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [COVID-19 and healthcare impacts](https://scholariq.org/topics/covid-19-and-healthcare-impacts/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)
- [Infection Control and Ventilation](https://scholariq.org/topics/infection-control-and-ventilation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.